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ABSTRACT
The maintenance of an effective level of oral hygiene is the cornerstone of all attempts to prevent and
control periodontal disease, and yet the widespread prevalence of the disease indicates the inability of
most people to maintain a level of plaque control commensurate with periodontal health. The inclusion
of antibacterial agents, such as chlorhexidine and triclosan, in oral care products has provided a means
to improve oral health. Randomised, controlled clinical trials have demonstrated that the unsupervised
use of a dentifrice (toothpaste) containing triclosan ⁄ copolymer signiﬁcantly improves gingival health,
prevents the onset of periodontitis and reduces further progression of tissue destruction. The delivery of
such beneﬁts has positive implications for the oral health of individuals and populations.
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INTRODUCTION
The inﬂammation causing periodontal diseases
is initiated by bacterial bioﬁlms (dental plaque)
that form on the surfaces of teeth in close
proximity to the supporting tissues of the teeth.
Initially, the bioﬁlms develop above (Fig. 1a) the
gum margin (supragingival) but, in the absence
of effective oral hygiene, will inevitably extend
below (Fig. 1b) the gum margin (subgingival).
The inﬂammatory and immune responses to
these bioﬁlms are primarily responsible for the
subsequent destruction of the periodontal tis-
sues. The most common forms of periodontal
disease are gingivitis and periodontitis. The
term gingivitis denotes a lesion that is conﬁned
to the gingiva (gum) and is reversible, provided
that the individual maintains an effective level
of plaque control. However, gingivitis is the
precursor of periodontitis, which is caused by
the apical spread of inﬂammation, and the
irreversible loss of tooth support. Gingivitis
and periodontitis are a continuum, and
although the susceptibility of an individual to
periodontitis is inﬂuenced by many factors, such
as smoking, diabetes and genetics, the weight of
evidence indicates that the prevention of gingi-
val inﬂammation prevents periodontitis [1].
Periodontal diseases are prevalent in popula-
tions around the world [2]. More than 82% of
US adolescents have overt gingival inﬂamma-
tion [2], and in Western Europe 36% of those
aged 35–44 years have moderate periodontitis
and approximately 10% have severe periodon-
titis [3]. The prevalence and severity of peri-
odontitis increases with age [4] and, as the
increasingly numerous elderly population retain
more of their teeth into later life, periodontal
disease will pose an increasing threat to their
natural dentition and, potentially, their general
health.
Although many factors inﬂuence the suscepti-
bility of an individual to periodontitis, the process
of tissue destruction is initiated by plaque bacte-
ria. The cornerstone of any attempt to prevent and
control periodontal disease is the maintenance of
an effective level of plaque control by the indi-
vidual at home, and available evidence indicates
that most people ﬁnd it difﬁcult to maintain this
level. In the UK, for example, 74% of adults
claimed to brush their teeth twice a day, and yet
72% of 25–34-year-olds had visible plaque on
30% of teeth, and those aged 65 years and over
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had visible plaque on 44% of teeth [4]. It was thus
concluded that there is a need to improve the oral
cleanliness of the majority of the population if
periodontal health is to be improved.
Conventional dentifrices (toothpastes) are com-
plex mixtures of abrasives, surfactants and
humectants that enhance the physical removal of
plaque bacteria from the tooth surfaces. The
principle and beneﬁts of adding chemical agents
to dentifrices is exempliﬁed by the inclusion of
ﬂuoride, which has been a major factor in reduc-
ing the prevalence of dental caries worldwide [5].
Given the importance of plaque bacteria in initi-
ating periodontal disease, the incorporation of an
antibacterial agent into oral care products would
appear to be a logical development. This review
will consider clinical studies, of at least 6 months’
duration, that have assessed the effectiveness of




Although launched initially in the 1950s to deliver
the anti-caries beneﬁt of ﬂuoride, dentifrices
containing stannous ﬂuoride also exhibit intrinsic
antimicrobial effects [6]. Stabilised stannous ﬂuo-
ride dentifrices improve gingival health as com-
pared with a conventional dentifrice, but this has
not always been accompanied by a signiﬁcant
reduction in plaque [7,8].
Triclosan
Triclosan is a broad-spectrum antibacterial agent
with a good safety record as used in many
consumer products, e.g., deodorants and soaps.
The fact that triclosan is a non-ionic molecule
allows it to be formulated in conventional denti-
frices, but it does not bind to the oral surfaces for
more than a few hours and therefore does not
deliver a sustained level of anti-plaque activity.
Two attempts have been made to overcome this
problem.
Triclosan ⁄ copolymer
The ﬁrst approach was to add a copolymer,
polyvinylmethyl ether maleic acid, which in-
creased the uptake of triclosan and its retention
[6] on oral surfaces (plaque, teeth and mucosa).
Subsequent studies have demonstrated that tri-
closan ⁄ copolymer dentifrices containing 0.3%
triclosan, 2.0% copolymer and ﬂuoride (1100 ⁄
1450 p.p.m. F) (Colgate Total, Colgate-Palmolive
company, NJ, USA) maintain concentrations of
triclosan in plaque that exceed the MIC values of
many plaque bacteria for up to 12 h [9].
The efﬁcacy of this triclosan ⁄ copolymer denti-
frice in reducing plaque and improving gingival
health has been assessed in numerous rando-
mised, controlled clinical trials, and the results
have been summarised in a number of traditional
and systematic reviews [10,11]. The participants in
all studies were adults with plaque and gingivitis
(a) (b)
Fig. 1. Supragingival plaque and
gingival inﬂammation (a). Subgin-
gival plaque and irreversible loss of
tooth support (b).
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[11]. Participants were randomly allocated to use
either the triclosan ⁄ copolymer dentifrice or a
conventional ﬂuoride dentifrice for 6 months.
They were given no oral hygiene instruction and
were simply asked to use their allocated dentifrice
twice a day. With the exception of one trial, all
dentifrices were supplied in plain white tubes.
The meta-analyses of data from 16 studies
demonstrated that the triclosan ⁄ copolymer den-
tifrice was signiﬁcantly more effective in improv-
ing plaque control and gingival health than a
ﬂuoride dentifrice. The weighted mean difference
(WMD) of )0.48 for the Quigley–Hein Plaque
Index corresponds to a 23% reduction in plaque
when compared with a ﬂuoride dentifrice. The
WMD of )0.15 for heavy plaque deposits corre-
sponds to a 15% reduction. In relative terms,
there was a 49% reduction in the proportion of
sites that had heavy plaque. The WMD of )0.26
for gingival inﬂammation corresponds to a 23%
reduction. The WMD of )0.34 for gingival bleed-
ing corresponds to a 12% reduction which, in
relative terms, corresponds to a 49% reduction in
the proportion of sites with bleeding.
The progression of gingivitis to periodontitis
is an unpredictable event, but bleeding sites are
more likely to progress to periodontitis than
non-bleeding sites [12]. Since the triclo-
san ⁄ copolymer dentifrice signiﬁcantly reduced
gingival bleeding, further studies have assessed
whether the dentifrice could also have beneﬁcial
effects on periodontitis. A 3-year randomised
clinical trial involving adolescents who were at
risk of developing early periodontitis demon-
strated that the triclosan ⁄ copolymer dentifrice
was indeed signiﬁcantly more effective than a
standard ﬂuoride toothpaste in preventing the
onset of periodontitis [13]. After 3 years,
the triclosan ⁄ copolymer dentifrice reduced the
amount of attachment loss (early periodontitis)
per subject by 50% and the number of affected
sites by 41%. In another 3-year study, which
involved patients who already had periodontitis,
the triclosan ⁄ copolymer dentifrice was signiﬁ-
cantly more effective than a ﬂuoride dentifrice
in reducing pocket depth and further attach-
ment loss [14]. Data from a 5-year clinical trial
in Australia demonstrated that the triclosan ⁄
copolymer dentifrice could slow the progression
of disease in a normal adult population [15].
Finally, the triclosan ⁄ copolymer dentifrice sig-
niﬁcantly improved the gingival health and
periodontal status in smokers when compared
with a standard ﬂuoride dentifrice [16].
No adverse events have been reported in any
of the studies, and no shifts in the microﬂora
of supragingival plaque favouring the growth of
either opportunistic or pathogenic bacterial or
yeast species have been observed [17,18].
Initially, the beneﬁts of triclosan ⁄ copolymer
dentifrice were attributed solely to the antibacte-
rial activity of triclosan, but several studies have
demonstrated that triclosan may also exert a
signiﬁcant anti-inﬂammatory effect. Triclosan
reduces skin and mucosal inﬂammation [19,20],
and there is clinical evidence that this may also
occur in the gingiva [21]. Further in-vitro studies
have demonstrated that triclosan reduces the
production of prostaglandin E2 by cells stimu-
lated with either interleukin-1b or tumour necro-
sis factor-a [22], and the production of
interleukin-1b by ﬁbroblasts stimulated by tu-
mour necrosis factor-a [23]. More recently, it has
been reported that triclosan reduces microsomal
prostaglandin E synthase-1 expression in human
gingival ﬁbroblasts [24].
Triclosan ⁄ zinc citrate
The second approach to overcoming the lack of
substantivity and efﬁcacy of triclosan has been to
combine triclosan with zinc citrate, the latter
having been shown to be substantive and to
inhibit plaque and gingivitis [25]. Several clinical
studies of at least 6 months’ duration have shown
that dentifrices containing zinc citrate and triclo-
san are signiﬁcantly more effective than a ﬂuoride




Chlorhexidine digluconate is the most powerful
anti-plaque agent available. Since 1970, numerous
clinical trials have demonstrated its effectiveness
in improving plaque control and gingival health
when used as an adjunct to toothbrushing [27]. Its
effectiveness is attributed to the dicationic nature
of chlorhexidine, which ensures its reversible
binding with the negatively charged molecules
in the oral cavity, so that activity persists for
several hours after application. However, its
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long-term use is precluded because of its pro-
pensity to stain the teeth, which is the result of
interactions between chlorhexidine on the tooth
surfaces and tannins in the diet.
Triclosan ⁄ copolymer
Three clinical trials of 6 months’ duration have
assessed the effectiveness of a mouthrinse con-
taining triclosan ⁄ copolymer [28]. Reductions in
plaque and gingivitis ranged from 24% to 36%
and from 19% to 23%, respectively, when com-
pared with a placebo rinse.
Cetylpyridinium chloride
Mouthrinses containing the cationic surface-
active agent cetylpyridinium chloride have been
marketed since 1940. When used as an adjunct to
toothbrushing, the rinse signiﬁcantly reduced
plaque and gingivitis by 28% and gingival bleed-
ing by 67%, respectively [29].
Essential oils
A combination of thymol and eucalyptol, together
with menthol and methylsalicylate in a hydroal-
cohol vehicle (Listerine, Johnson & Johnson,
Raritan, NJ, USA), is also used. Several clinical
trials [30,31] have demonstrated that when used
as an adjunct, this antiseptic mouthwash provides
signiﬁcant beneﬁts, with up to 56% reductions in
plaque and 35% reductions in gingivitis. How-
ever, in general, it has been found to be less
effective than chlorhexidine.
Amine ﬂuoride ⁄ stannous ﬂuoride
Although clinical studies of short duration have
generally shown an amine ﬂuoride ⁄ stannous
ﬂuoride rinse to improve plaque control and
gingival health [32], these beneﬁts have not been
consistently demonstrated in long-term studies.
In a clinical study of 7 months’ duration, an
amine ﬂuoride ⁄ stannous ﬂuoride rinse reduced
plaque by 5% and gingival bleeding by 30%
when compared with a placebo rinse, but no
beneﬁt to gingival health has been observed [33].
In 1996, it was reported that a combination of
amine ⁄ stannous ﬂuoride dentifrice and amine ⁄
stannous ﬂuoride mouthrinse was no more effec-
tive than a conventional ﬂuoride dentifrice and
rinse in improving plaque control and gingival
health. Subsequent studies have reported that
the combination of amine ⁄ stannous ﬂuoride den-
tifrice and rinse signiﬁcantly reduced plaque by
25% and 16% [33] but failed to deliver gingival
beneﬁts when compared with a conventional
ﬂuoride dentifrice and mouthrinse.
CONCLUSION
The need for effective control of dental plaque has
led to a large number of clinical studies with
antibacterial agents in oral hygiene formulations.
Antibacterial agents have been shown to vary in
their effectiveness in improving plaque control
and gingival health when compared to a conven-
tional ﬂuoride dentifrice in studies of at least
6 months’ duration. The unsupervised use of a
dentifrice containing triclosan ⁄ copolymer has
been shown to prevent the onset and progression
of periodontitis for at least 3 years. Such improve-
ments in periodontal health could have beneﬁcial
effects on systemic health.
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